GRAIL (NASDAQ:GRAL) CEO Sells $6,006,318.48 in Stock

GRAIL, Inc. (NASDAQ:GRAL) CEO Joshua Ofman sold 61,452 shares of the business’s stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $97.74, for a total transaction of $6,006,318.48. Following the completion of the sale, the chief executive officer owned 362,271 shares in the company, valued at $35,408,367.54. This represents a 14.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

GRAIL Trading Up 1.3%

NASDAQ:GRAL opened at $126.89 on Friday. The firm has a 50-day moving average price of $78.42 and a two-hundred day moving average price of $65.68. GRAIL, Inc. has a twelve month low of $41.50 and a twelve month high of $127.67. The company has a market capitalization of $5.67 billion, a P/E ratio of -13.01 and a beta of 3.25.

GRAIL (NASDAQ:GRAL) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.66) by $0.10. The company had revenue of $44.69 million for the quarter, compared to the consensus estimate of $42.39 million. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. On average, equities research analysts predict that GRAIL, Inc. will post -10.41 earnings per share for the current year.

Institutional Investors Weigh In On GRAIL

Several hedge funds have recently modified their holdings of the stock. BlackRock Inc. boosted its holdings in shares of GRAIL by 20.5% in the 2nd quarter. BlackRock Inc. now owns 3,577,075 shares of the company’s stock valued at $244,207,000 after purchasing an additional 608,539 shares during the last quarter. State Street Corp raised its position in shares of GRAIL by 26.1% in the 2nd quarter. State Street Corp now owns 2,385,514 shares of the company’s stock worth $162,859,000 after buying an additional 493,621 shares during the period. Primecap Management Co. CA acquired a new position in GRAIL in the second quarter valued at $148,836,000. Baker BROS. Advisors LP boosted its holdings in GRAIL by 27.9% in the fourth quarter. Baker BROS. Advisors LP now owns 2,085,333 shares of the company’s stock valued at $178,484,000 after acquiring an additional 455,208 shares during the last quarter. Finally, Bank of America Corp DE grew its position in GRAIL by 29.0% during the first quarter. Bank of America Corp DE now owns 914,114 shares of the company’s stock valued at $47,241,000 after acquiring an additional 205,611 shares during the period.

Key GRAIL News

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: FDA advisers recommended approval of Galleri after supporting its safety and narrowly endorsing its efficacy. A final FDA ruling is expected in the coming months; approval could expand insurance coverage, market access and adoption of GRAIL’s primary product. Reuters FDA panel article
• Positive Sentiment: The regulatory catalyst has driven a substantial weekly rally and helped GRAL reach a new 52-week high, as investors price in the potential commercial impact of FDA approval. Seeking Alpha FDA panel article
• Neutral Sentiment: Analyst sentiment remains cautious following the rally. Mizuho raised its price target to $100 from $65 but maintained a neutral rating, while RBC Capital reiterated its hold rating. These targets remain below recent trading levels, suggesting analysts view much of the FDA optimism as already reflected in the valuation. RBC Capital hold rating
• Negative Sentiment: The panel’s narrow efficacy endorsement leaves regulatory and adoption risks unresolved. Galleri’s commercial opportunity depends on final FDA approval, physician and insurer acceptance, and evidence that the test improves patient outcomes. Yahoo Finance FDA panel valuation article
• Negative Sentiment: Insider selling may weigh modestly on sentiment: CEO Joshua Ofman sold 61,452 shares and CFO Aaron Freidin sold 4,100 shares under pre-arranged Rule 10b5-1 plans. The transactions are less concerning than discretionary sales but can add pressure after the sharp advance. GRAIL insider sale article

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on GRAL. Weiss Ratings reissued a “sell (d-)” rating on shares of GRAIL in a research report on Friday, July 17th. Mizuho lifted their target price on shares of GRAIL from $65.00 to $100.00 and gave the stock a “neutral” rating in a research note on Friday. The Goldman Sachs Group started coverage on GRAIL in a report on Friday, June 5th. They issued a “neutral” rating and a $60.00 price target for the company. UBS Group set a $84.00 price target on GRAIL in a research note on Thursday, September 17th. Finally, Royal Bank Of Canada assumed coverage on GRAIL in a report on Thursday, September 17th. They set a “sector perform” rating and a $84.00 price objective on the stock. Five equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $78.60.

GRAIL Company Profile

GRAIL, Inc is a healthcare company focused on developing blood-based tests for the early detection of cancer. Its technology uses genomic and epigenomic signals, including patterns of DNA methylation, to identify signals associated with multiple cancer types from a single blood sample.

The company’s primary product is Galleri, a prescription blood test designed to screen for signals of more than 50 types of cancer, including cancers that currently lack recommended screening methods. Galleri is intended to complement, not replace, guideline-recommended cancer screenings, and a positive result requires follow-up diagnostic testing to determine whether cancer is present and where it may be located.

GRAIL was founded in 2016 as a subsidiary of Illumina and became an independent publicly traded company following its separation from Illumina in 2021.